☆ 4.6 Article

Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors

CHINESE MEDICAL JOURNAL (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Cell Biology

Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era

Laura Kalfeist et al.

Summary: Glucocorticoids are widely prescribed drugs in cancer patients due to their anti-inflammatory, anti-oedema, and anti-allergy properties. They are used in various clinical situations in oncology, including managing cancer-related symptoms and preventing or treating side effects or immune-related adverse events of anti-cancer therapies. Moreover, glucocorticoids have been found to affect immune response and tumor efficacy.

CELLS (2022)

添加到收藏夹

Article Oncology

Surgical Outcomes of Lobectomy Versus Limited Resection for Clinical Stage I Ground-Glass Opacity Lung Adenocarcinoma 2 Centimeters or Smaller

Giannis Mountzios et al.

Summary: For patients with clinical stage I ground-glass opacity (GGO) lung adenocarcinomas with maximum diameters ≤2 cm, lobectomy and limited resection are comparable oncologic procedures. However, lobectomy resulted in better survival for patients with solid-dominant tumors in this population.

CLINICAL LUNG CANCER (2021)

添加到收藏夹

Article Immunology

Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment

Ying Wang et al.

Summary: The use of corticosteroids for cancer-related indications in lung cancer patients receiving ICI treatment is associated with poorer prognosis, as demonstrated by meta-analysis and retrospective analysis. Subgroup analysis focusing on non-small cell lung cancer (NSCLC) showed similar results, highlighting the importance of careful selection of corticosteroid-treated patients for ICI therapy in personalized clinical management.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Oncology

Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers

Riccardo Lobefaro et al.

Summary: The study found that for patients with Non-Small Cell Lung Cancer, the worse the Performance Status (PS) is, the lower the efficacy of immunotherapy, with patients with PS2 showing poorer outcomes in terms of disease control rate, progression free survival, and overall survival. Additionally, LDH levels and corticosteroid exposure were also associated with patient outcomes.

LUNG CANCER (2021)

添加到收藏夹

Article Medicine, General & Internal

Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020

Wei Cao et al.

Summary: This study summarized the recent changing profiles of cancer burden worldwide and in China, revealing that breast cancer became the most diagnosed cancer globally in 2020. China accounted for 24% of newly diagnosed cases and 30% of cancer-related deaths worldwide in 2020, with a high cancer mortality rate.

CHINESE MEDICAL JOURNAL (2021)

添加到收藏夹

Article Oncology

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

Alessio Cortellini et al.

Summary: The study reveals the negative impact of antibiotics (ATB) on pembrolizumab monotherapy outcomes in NSCLC, while corticosteroids and proton pump inhibitors (PPIs) may worsen baseline performance status. These findings highlight the underlying immune-modulatory effects of these concomitant medications.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Impact of corticosteroid use on outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Hongchuan Zhang et al.

Summary: By conducting a meta-analysis of 14 studies, it was found that NSCLC patients receiving corticosteroids during ICI therapy had significantly reduced OS and PFS. Clinicians and oncologists should take this information into consideration when prescribing corticosteroids for this specific population.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2021)

添加到收藏夹

Article Oncology

Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina

Claudio Martin et al.

CLINICAL LUNG CANCER (2020)

添加到收藏夹

Article Oncology

Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer

Martin Svaton et al.

ANTICANCER RESEARCH (2020)

添加到收藏夹

Article Oncology

Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer

Ou Yamaguchi et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)

添加到收藏夹

Article Oncology

First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status

Francesco Facchinetti et al.

EUROPEAN JOURNAL OF CANCER (2020)

添加到收藏夹

Article Oncology

Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status

Yuichi Adachi et al.

CANCER MEDICINE (2020)

添加到收藏夹

Article Oncology

Poor efficacy of anti-programmed cell death-1/ligand 1 monotherapy for non-small cell lung cancer patients with active brain metastases

Takehiro Tozuka et al.

THORACIC CANCER (2020)

添加到收藏夹

Article Oncology

Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%

Giulio Metro et al.

JOURNAL OF IMMUNOTHERAPY (2020)

添加到收藏夹

Review Chemistry, Medicinal

Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy

Leilei Ai et al.

DRUG DESIGN DEVELOPMENT AND THERAPY (2020)

添加到收藏夹

Article Oncology

Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)

Andrea De Giglio et al.

CANCERS (2020)

添加到收藏夹

Article Oncology

Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents

Mariona Riudavets et al.

FRONTIERS IN ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma

Alexandra Drakaki et al.

ONCOIMMUNOLOGY (2020)

添加到收藏夹

Article Oncology

Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors

Lizza E. L. Hendriks et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)

Motohiro Tamiya et al.

INVESTIGATIONAL NEW DRUGS (2019)

添加到收藏夹

Article Oncology

Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications

Biagio Ricciuti et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Glucocorticoids potentiate the inhibitory capacity of programmed cell death 1 by up-regulating its expression on T cells

Natsumi Maeda et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2019)

添加到收藏夹

Article Oncology

Is there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients?

Audrey Bellesoeur et al.

CANCERS (2019)

添加到收藏夹

Article Oncology

Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors

Giovanni Fuca et al.

ESMO OPEN (2019)

添加到收藏夹

Article Oncology

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Julie R. Brahmer et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab

Susan C. Scott et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab

Coraline Dumenil et al.

PLOS ONE (2018)

添加到收藏夹

Article Oncology

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer

Kathryn C. Arbour et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

I. Puzanov et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)

添加到收藏夹

Article Oncology

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

J. B. A. G. Haanen et al.

ANNALS OF ONCOLOGY (2017)

添加到收藏夹

Article Oncology

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

F. Roila et al.

ANNALS OF ONCOLOGY (2016)

添加到收藏夹

Article Health Care Sciences & Services

Testing the Newcastle Ottawa Scale showed low reliability between individual reviewers

Lisa Hartling et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2013)

添加到收藏夹

Editorial Material Health Care Sciences & Services

Dyspnea in Palliative Care: Expanding the Role of Corticosteroids

Richard J. Lin et al.

JOURNAL OF PALLIATIVE MEDICINE (2012)

添加到收藏夹

Article Medicine, General & Internal

How to obtain the confidence interval from a P value

Douglas G. Altman et al.

BMJ-BRITISH MEDICAL JOURNAL (2011)

添加到收藏夹

Review Oncology

The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline

Timothy C. Ryken et al.

JOURNAL OF NEURO-ONCOLOGY (2010)

添加到收藏夹

Article Medicine, Research & Experimental

Practical methods for incorporating summary time-to-event data into meta-analysis

Jayne F. Tierney et al.

TRIALS (2007)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.